Henry RR, Ratner RE, Stonehouse AH, et al
Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
Recent phase 3 research involving oral semaglutide in early Alzheimers disease has also reinforced the need for caution: promising biology does not always translate into meaningful clinical benefit
Weight loss may be associated with other symptoms including but not limited to muscle loss, fatigue, menstrual changes, gallstones, and mood changes